Stifel Downgrades Chinook Therapeutics to Hold, Lowers Price Target to $41
Portfolio Pulse from richadhand@benzinga.com
Stifel analyst Alex Thompson downgrades Chinook Therapeutics (NASDAQ:KDNY) from Buy to Hold and lowers the price target from $43 to $41.

June 13, 2023 | 11:25 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Chinook Therapeutics downgraded to Hold by Stifel, with a lowered price target of $41.
The downgrade from Buy to Hold and the lowering of the price target by Stifel analyst Alex Thompson may negatively impact Chinook Therapeutics' stock price in the short term, as it indicates a less optimistic outlook for the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100